Ultragenyx Pharmaceutical
RARE
164 hedge funds and large institutions have $2.76B invested in Ultragenyx Pharmaceutical in 2017 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 66 increasing their positions, 59 reducing their positions, and 25 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 59
9% less call options, than puts
Call options by funds: $9.32M | Put options by funds: $10.2M
4.28% less ownership
Funds ownership: 101.88% → 97.59% (-4.3%)
6% less capital invested
Capital invested by funds: $2.93B → $2.76B (-$167M)
6% less funds holding
Funds holding: 174 → 164 (-10)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$241M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$89.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 5 |
FAM
Fred Alger Management
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$51.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$37.2M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$23.7M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$18.6M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$16.6M |
RARE Hedge Fund Activity: Q1 2017 in Review
164 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2017, worth a combined $2.76B — down 5.7% from $2.93B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of RARE and 22 opened new positions — a net loss of 3 holders — while 59 trimmed existing stakes and 66 added.
The largest buyer was BlackRock, adding an estimated $241M. The largest seller was Wellington Management Group, cutting an estimated $51.4M.
- 164 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2017, down from 174 in Q4 2016.
- Funds reported $2.76B of Ultragenyx Pharmaceutical stock for Q1 2017, down 5.7% quarter-over-quarter.
- 22 funds opened new Ultragenyx Pharmaceutical positions in Q1 2017 and 25 closed out, a net change of -3 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2017 was BlackRock, an estimated $241M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2017 was Wellington Management Group, an estimated $51.4M sold.
Based on aggregated 13F filings for Q1 2017.